- Home
- AARD vs CODA Comparison
AARD vs CODA Comparison
Compare AARD & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | CODA |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.4M | 114.7M |
| IPO Year | 2025 | 2007 |
Fundamental Metrics
Financial Performance| Metric | AARD | CODA |
|---|---|---|
| Price | $1.50 | $9.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | $11.11 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 108.4K | 75.8K |
| Earning Date | 11-12-2026 | 09-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.11 | 15.62 |
| EPS | N/A | ★ 0.36 |
| Revenue | N/A | ★ $20,316,161.00 |
| Revenue This Year | N/A | $9.92 |
| Revenue Next Year | N/A | $17.26 |
| P/E Ratio | ★ N/A | $25.32 |
| Revenue Growth | N/A | ★ 4.98 |
| 52 Week Low | $3.35 | $7.80 |
| 52 Week High | $16.60 | $18.00 |
Technical Indicators
Market Signals| Indicator | AARD | CODA |
|---|---|---|
| Relative Strength Index (RSI) | 20.61 | 28.45 |
| Support Level | N/A | $9.08 |
| Resistance Level | $5.88 | $10.66 |
| Average True Range (ATR) | 0.55 | 0.36 |
| MACD | -0.17 | -0.14 |
| Stochastic Oscillator | 1.00 | 9.09 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.